Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast
Language English Country Switzerland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
12579210
DOI
10.1007/bf03036739
Knihovny.cz E-resources
- MeSH
- Alleles MeSH
- Alternative Splicing MeSH
- Point Mutation MeSH
- DNA Primers MeSH
- DNA-Directed DNA Polymerase metabolism MeSH
- Genetic Techniques MeSH
- Genes, p53 * MeSH
- Introns MeSH
- Leukemia genetics MeSH
- Humans MeSH
- RNA, Messenger genetics MeSH
- Mutagenesis, Site-Directed MeSH
- Tumor Suppressor Protein p53 genetics MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Polymerase Chain Reaction methods MeSH
- Reproducibility of Results MeSH
- RNA genetics MeSH
- Saccharomyces cerevisiae genetics MeSH
- Base Sequence MeSH
- Substrate Specificity MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- DNA Primers MeSH
- DNA-Directed DNA Polymerase MeSH
- RNA, Messenger MeSH
- Tumor Suppressor Protein p53 MeSH
- RNA MeSH
Tumor suppressor p53 is transcription factor that participates in control of many cellular functions. Somatic mutations of the p53 gene are frequently detected in human cancers. Several methods can be used for identification of p53 mutations, including FASAY - functional analysis of separated alleles in yeast. FASAY distinguishes yeast colonies expressing functional p53 protein from colonies producing a dysfunctional p53 protein simply on the basis of color. The validity of the method depends on a low background level. There are several sources of background as PCR-induced point mutations, low quality of RNA and alternative splicing of intron 9 affecting the p53 carboxy-terminus. In the present work we show that FASAY can be successfully used for analysis of mRNA isolated from blood samples that were collected and stored for 24 hours at 0 degrees C without undesired increase of background. We also measured fidelity of several commonly used DNA polymerases and determined the most suitable kinds of Pfu DNA polymerases for FASAY. Reaction conditions described in this report allow routine analysis of p53 status in leukemic cells using FASAY.
See more in PubMed
Int J Cancer. 1994 Apr 1;57(1):1-9 PubMed
Oncogene. 1997 Mar 20;14(11):1307-13 PubMed
Oncogene. 1998 May 14;16(19):2527-39 PubMed
Oncogene. 1998 Mar 12;16(10):1369-72 PubMed
Tumour Biol. 2001 Mar-Apr;22(2):59-66 PubMed
J Mol Diagn. 2000 Aug;2(3):139-44 PubMed
Gene. 1990 Oct 30;95(1):91-8 PubMed
Cell Prolif. 2001 Feb;34(1):1-14 PubMed
Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963-7 PubMed
Nat Genet. 1993 Oct;5(2):124-9 PubMed
Oncogene. 1996 Feb 15;12(4):813-8 PubMed
Leukemia. 1992 Aug;6(8):839-42 PubMed
Oncogene. 1997 Nov 27;15(22):2667-74 PubMed
Cancer Res. 1997 Oct 1;57(19):4285-300 PubMed
Science. 1990 Aug 24;249(4971):912-5 PubMed
Nucleic Acids Res. 1994 Aug 11;22(15):3259-60 PubMed
Oncology. 2001;60(2):176-88 PubMed
Oncogene. 1997 Jan 16;14(2):163-9 PubMed
Br J Cancer. 1998 May;77(9):1429-38 PubMed
Neoplasma. 1999;46(6):384-9 PubMed
Germline mutation in the TP53 gene in uveal melanoma
TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods
